New bladder gel could help patients avoid bladder removal surgery

NCT ID NCT07468851

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new treatment called HS-10566, a gel that delivers the chemotherapy drug gemcitabine directly into the bladder. It is for people with high-risk non-muscle-invasive bladder cancer who cannot or choose not to have their bladder removed. The trial will check if the treatment is safe, tolerable, and effective at controlling the cancer. About 180 adults will take part in this early-phase study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HS-10566 (a gel that delivers the chemotherapy drug gemcitabine directly into the bladder)
What this could lead to
If successful, this could offer a bladder-sparing treatment option for patients with high-risk bladder cancer who cannot or choose not to have their bladder removed.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so safety and effectiveness are not yet proven. The treatment may not work for everyone and could cause side effects from the chemotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Nanjing Drum Tower Hospital

    Nanjing, 210008, China

  • Peking University First Hospital

    Beijing, 100034, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.